FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Tenenbaum Fabian</u> | | | | | 2. Issuer Name and Ticker or Trading Symbol Bellerophon Therapeutics, Inc. [BLPH] | | | | | | | eck all applic | , | | on(s) to Issu 10% Ow Other (s) | ner |
|--|---|--|--|-----------------------------------|---|--------|------------------|--|--------------------|--|---|---|--|----|--|--|
| (Last) (First) (Middle) 184 LIBERTY CORNER ROAD SUITE 302 | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 01/02/2019 | | | | | | | X Officer (give title below) Chief Executive Officer | | | | |
| (Street) WARREN NJ | | 07059 | 4. | If Ame | ndment, [| Date (| of Original File | nal Filed (Month/Day/Year) | | | Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) | (Si | - | (Zip) | | | | | | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | |
| Date | | | | Transaction ate lonth/Day/Y | Execution Date | | | Transaction Disposed Code (Instr. 5) | | ities Acquired (A) or d Of (D) (Instr. 3, 4 and | | 5. Amour Securitie Beneficia Owned F Reported | s Forn Illy (D) o ollowing (I) (Ir | | Direct Conditions of the condi | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | | | | Code V | Amount | (A) or (D) | Price | Transact (Instr. 3 a | ion(s) | | | iiisu. 4) | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date if any (Month/Day/Yea | Code (| | | | 6. Date Exerc Expiration Da (Month/Day/\ | ate | 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4) | ly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | |
| Stock Option (right to buy) | \$0.88 | 01/02/2019 | | A | | 12,500 | | (1) | 01/02/2029 | Common Stock | 12,500 | \$0 | 3,688,69 | 97 | D | |

Explanation of Responses:

1. 1. This option was granted on January 2, 2019. This option vests in quarterly installments over a four-years period from the date of grant.

Remarks:

/s/ Fabian Tenenbaum

01/02/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.